$PRLD
Prelude Therapeutics Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021056509 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.115M $2.850M $2.861M
YoY Change 184.74% 105.04%
% of Gross Profit
Research & Development $22.72M $15.29M $18.31M
YoY Change 48.57% 178.56%
% of Gross Profit
Depreciation & Amortization $266.0K $140.0K $270.0K
YoY Change 90.0% 55.56% 68.75%
% of Gross Profit
Operating Expenses $30.84M $18.14M $11.44M
YoY Change 69.95% 163.57%
Operating Profit -$30.84M -$18.14M -$11.44M
YoY Change 69.95% 163.57%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $149.0K $1.384M $28.00K
YoY Change -89.23% 822.67%
Pretax Income -$30.69M -$16.76M -$20.92M
YoY Change 83.1% 149.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.69M -$16.76M -$11.41M
YoY Change 83.1% 149.03% 105.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$662.3K -$5.254M -$4.899M
COMMON SHARES
Basic Shares Outstanding 46.33M
Diluted Shares Outstanding 46.33M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $320.9M $234.8M $29.70M
YoY Change 36.65%
Cash & Equivalents $61.42M $234.8M $29.72M
Short-Term Investments $259.4M
Other Short-Term Assets $5.032M $3.300M $1.000M
YoY Change 52.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $325.9M $238.1M $30.70M
YoY Change 36.87%
LONG-TERM ASSETS
Property, Plant & Equipment $5.320M $1.600M $1.600M
YoY Change 232.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $500.0K
YoY Change
Total Long-Term Assets $5.320M $1.581M $2.000M
YoY Change 236.5%
TOTAL ASSETS
Total Short-Term Assets $325.9M $238.1M $30.70M
Total Long-Term Assets $5.320M $1.581M $2.000M
Total Assets $331.2M $239.7M $32.70M
YoY Change 38.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.06M $5.074M $3.500M
YoY Change 118.01%
Accrued Expenses $6.765M $6.285M $1.700M
YoY Change 7.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $100.0K
YoY Change
Total Short-Term Liabilities $19.66M $11.36M $5.600M
YoY Change 73.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $312.0K $15.00K $0.00
YoY Change 1980.0%
Total Long-Term Liabilities $312.0K $15.00K $0.00
YoY Change 1980.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.66M $11.36M $5.600M
Total Long-Term Liabilities $312.0K $15.00K $0.00
Total Liabilities $19.98M $11.37M $5.700M
YoY Change 75.62%
SHAREHOLDERS EQUITY
Retained Earnings -$186.3M -$88.18M
YoY Change 111.28%
Common Stock $316.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $311.2M $228.3M -$69.31M
YoY Change
Total Liabilities & Shareholders Equity $331.2M $239.7M $32.70M
YoY Change 38.19%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$30.69M -$16.76M -$11.41M
YoY Change 83.1% 149.03% 105.33%
Depreciation, Depletion And Amortization $266.0K $140.0K $270.0K
YoY Change 90.0% 55.56% 68.75%
Cash From Operating Activities -$21.77M -$12.51M -$18.82M
YoY Change 74.05% 122.2% 62.66%
INVESTING ACTIVITIES
Capital Expenditures -$659.0K -$170.0K -$120.0K
YoY Change 287.65% -138.64% -14.29%
Acquisitions
YoY Change
Other Investing Activities -$260.0M
YoY Change
Cash From Investing Activities -$260.6M -$170.0K -$120.0K
YoY Change 153212.94% -61.36% -14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 711.0K 217.8M 29.78M
YoY Change -99.67% -725966.67% -0.23%
NET CHANGE
Cash From Operating Activities -21.77M -12.51M -18.82M
Cash From Investing Activities -260.6M -170.0K -120.0K
Cash From Financing Activities 711.0K 217.8M 29.78M
Net Change In Cash -281.7M 205.1M 10.84M
YoY Change -237.36% -3461.97% -40.24%
FREE CASH FLOW
Cash From Operating Activities -$21.77M -$12.51M -$18.82M
Capital Expenditures -$659.0K -$170.0K -$120.0K
Free Cash Flow -$21.12M -$12.34M -$18.70M
YoY Change 71.11% 103.29% 63.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.72
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M7D
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2480000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2107000
CY2020Q4 prld Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
301000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3920000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7455000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1836000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
312000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
319605000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-176000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186278000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
311242000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
331217000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61600000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33605000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19125000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5712000
us-gaap Operating Expenses
OperatingExpenses
80725000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1873000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1638000
us-gaap Net Income Loss
NetIncomeLoss
-78852000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.83
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46330794
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45841049
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2380100
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16760000
us-gaap Net Income Loss
NetIncomeLoss
-78852000
us-gaap Net Income Loss
NetIncomeLoss
-37679000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-176000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-176000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30863000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39317000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1384000
us-gaap Net Income Loss
NetIncomeLoss
-37679000
us-gaap Operating Expenses
OperatingExpenses
39317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-80725000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
149000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
212183000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3194471
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22721000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15293000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8115000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2851000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
30836000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
18144000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30836000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18144000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30687000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16760000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.25
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
711000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16760000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79028000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37679000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
386000
CY2021Q1 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
739000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161412000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3886000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21300000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
356567000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
334361000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4237000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26865000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
96000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-176000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7033000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30687000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
311242000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49412000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
362000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9511000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161424000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
258000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1519000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-58561000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
627000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11408000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-69311000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
146211000
CY2020Q3 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
2538000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
166630000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1472000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16760000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
228307000
us-gaap Profit Loss
ProfitLoss
-78852000
us-gaap Profit Loss
ProfitLoss
-37679000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
625000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
409000
prld Noncash Lease Expense
NoncashLeaseExpense
928000
us-gaap Share Based Compensation
ShareBasedCompensation
15156000
us-gaap Share Based Compensation
ShareBasedCompensation
2461000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-356000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2532000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1924000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7834000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1931000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-393000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3472000
prld Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
951000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57829000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31330000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
259973000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2026000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
292000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-261999000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-292000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167929000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
162943000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
247535000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-156885000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
215913000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18879000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61424000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
234792000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
567000
CY2021Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
97000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
90000
prld Unrealized Gain Loss On Marketable Securities
UnrealizedGainLossOnMarketableSecurities
-176000
prld Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
1079000
prld Offering Costs In Accrued Expenses And Other Current Liabilities
OfferingCostsInAccruedExpensesAndOtherCurrentLiabilities
220000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.</p>
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3614000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8843129
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7961906
CY2021Q3 prld Offset Accrued Expense And Other Current Liabilities To Eliminate Deferred Rent
OffsetAccruedExpenseAndOtherCurrentLiabilitiesToEliminateDeferredRent
64000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
259617000
CY2021Q3 prld Available For Sale Debt Securities Accumulated Gross Unrealized Gain Net Of Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax
34000
CY2021Q3 prld Available For Sale Debt Securities Accumulated Gross Unrealized Loss Net Of Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
210000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
259441000
CY2021Q3 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
2687000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3508000
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2020Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
3421000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
570000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
420000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6765000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7455000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
This option to extend was not recognized as part of the Company’s measurement of the right-of-use asset and operating lease liability as of September 30, 2021
prld Operating Lease Estimated Incremental Borrowing Rate Percent
OperatingLeaseEstimatedIncrementalBorrowingRatePercent
0.100
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2021Q2 prld Lease Commencement Date
LeaseCommencementDate
2021-07-01
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-06-30
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
459000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1836000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2295000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
147000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2148000
prld Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7033000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1472000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15156000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2461000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6839091
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2228869
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.82
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
611124
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
365147
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
21.68
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8091689
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.30
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2094067
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.10
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
139300000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
52800000
CY2021Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8091689
CY2021Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2094067

Files In Submission

Name View Source Status
0001564590-21-056509-index-headers.html Edgar Link pending
0001564590-21-056509-index.html Edgar Link pending
0001564590-21-056509.txt Edgar Link pending
0001564590-21-056509-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
prld-10q_20210930.htm Edgar Link pending
prld-10q_20210930_htm.xml Edgar Link completed
prld-20210930.xsd Edgar Link pending
prld-20210930_cal.xml Edgar Link unprocessable
prld-20210930_def.xml Edgar Link unprocessable
prld-20210930_lab.xml Edgar Link unprocessable
prld-20210930_pre.xml Edgar Link unprocessable
prld-ex311_9.htm Edgar Link pending
prld-ex312_7.htm Edgar Link pending
prld-ex321_8.htm Edgar Link pending
prld-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending